DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/qx35dm/lexicons_lx4211) has announced the addition of the "Lexicon's LX-4211 - a novel mechanism to treat diabetes" report to their offering.
Lexicon's LX-4211 is in phase II development for the treatment of type 2 diabetes. It belongs to a novel class of agents that inhibits sodium-glucose transporters (SGLTs). Most candidates in this new class are very selective for SGLT2, which is located primarily in the kidney. There it transports glucose that the kidney has filtered into the urine back into the blood. Thus, these agents lower blood glucose by blocking its reabsorption. In contrast to most agents in this class, LX-4211 also inhibits SGLT1. That transporter is found primarily in the gut where it facilitates the absorption of dietary glucose.
This report explores the prospects and implications of this novel mechanism of action and available data from early LX-4211 clinical trials. Notably, it also reviews the BMS/AZN's dapagliflozin program in detail, with regard to efficacy and safety issues. Dapagliflozin is a selective SGLT2 inhibitor that is currently under review by FDA, and a bellwether for LX-4211 and the class.
Key Topics Covered:
1. Type-2 diabetes
2. Sodium glucose transport (SGLT) inhibition as a new approach
1. Phase I studies compared three formulations and evaluated dose timing
2. The Iia study (Study 201) assessed activity over 28 days
1. Insights from the preliminary LX-4211
2. What does the pharmacology tell us about potential benefits and risks?
- Preclinical data lend insight
- Genetic deletions/mutations of glucose transporters may mimic effects of inhibition
- Early LX-4211 data are consistent with the proposed pharmacology
3. Dapagliflozin is an important bellweather of FDA's views about the class
- Preclinical toxicology and early human pharmacology studies
- The current status
- What lessons for LX-4211 can be learned from the dapagliflozin program?
4. What does FDA guidance teach us about the path forward?
- General guidance for diabetes therapies
- Diabetes drugs and cardiovascular risk
1. Overview of the diabetes market
- Revenue shares provide another window into the diabetes market
- Prescription shares provide another view of the diabetes market
For more information visit http://www.researchandmarkets.com/research/qx35dm/lexicons_lx4211
Source: Research and Markets